Second-line treatment for malignant pleural mesothelioma

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Malignant pleural mesothelioma (MPM) often requires chemotherapy, with cisplatin and pemetrexed as a preferred first-line option.
• Nearly all MPM patients experience disease progression after initial treatment, necessitating exploration of second-line therapies.

Purpose of the Study:

• To review current evidence and define optimal second-line treatment strategies for malignant pleural mesothelioma.
• To identify potential future therapeutic avenues for MPM patients who progress on first-line therapy.

Main Methods:

• Review of clinical trial data and expanded access programs for second-line chemotherapy in MPM.
• Analysis of treatment outcomes for pemetrexed-naïve and pemetrexed-pre-treated patient populations.

Main Results:

• Single-agent pemetrexed is suggested as a standard second-line treatment for pemetrexed-naïve MPM patients.
• Re-treatment with pemetrexed may be considered for selected patients with prolonged response to initial therapy.
• Vinorelbine serves as a palliative option when trials or experimental approaches are unavailable.

Conclusions:

• Second-line chemotherapy plays an increasing role in MPM management, though optimal regimens are still under investigation.
• Further research into novel agents and therapeutic strategies is crucial for improving outcomes in pre-treated MPM patients.